Skip to main content
. Author manuscript; available in PMC: 2025 Aug 25.
Published in final edited form as: J Orthop Sports Med. 2025 Jul 7;7(3):311–327. doi: 10.26502/josm.511500210

Figure 3:

Figure 3:

(A) The flowchart depicts the most common approach and guideline to pharmacological thromboprophylaxis involved in total knee arthroplasty (TKA) and total hip arthroplasty (THA). (B) The strengths and weaknesses of using the anticoagulants that are discussed in the article, highlighting the importance of individualized care based on patient related risk factors. CrCl, creatinine clearance; DOACs, direct oral anticoagulants; INR, international normalized ratio; LMWH, low molecular weight heparin; MI, myocardial infarction; VTE, venous thromboembolism.